Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
7.31
+0.02 (0.27%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Kezar Life Sciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | - | 7 | - | - | |
| Cost of Revenue | 33.76 | 65.74 | 85.7 | 51.01 | 38.94 | |
| Gross Profit | -33.76 | -65.74 | -78.7 | -51.01 | -38.94 | |
| Selling, General & Admin | 18.51 | 23.39 | 26.54 | 20.15 | 15.72 | |
| Operating Expenses | 18.51 | 23.39 | 26.54 | 20.15 | 15.72 | |
| Operating Income | -52.27 | -89.14 | -105.24 | -71.16 | -54.66 | |
| Interest Expense | -0.9 | -1.6 | -1.6 | -1.19 | -0.16 | |
| Interest & Investment Income | 4.44 | 8.46 | 11.1 | 4.11 | 0.19 | |
| Other Non Operating Income (Expenses) | -0.47 | 0.01 | 0.05 | - | - | |
| EBT Excluding Unusual Items | -49.2 | -82.27 | -95.68 | -68.24 | -54.63 | |
| Merger & Restructuring Charges | -6.84 | -1.47 | -6.19 | - | - | |
| Pretax Income | -56.03 | -83.74 | -101.87 | -68.24 | -54.63 | |
| Net Income | -56.03 | -83.74 | -101.87 | -68.24 | -54.63 | |
| Net Income to Common | -56.03 | -83.74 | -101.87 | -68.24 | -54.63 | |
| Shares Outstanding (Basic) | 7 | 7 | 7 | 7 | 5 | |
| Shares Outstanding (Diluted) | 7 | 7 | 7 | 7 | 5 | |
| Shares Change (YoY) | 0.36% | 0.48% | 7.70% | 27.69% | 19.90% | |
| EPS (Basic) | -7.66 | -11.49 | -14.04 | -10.13 | -10.35 | |
| EPS (Diluted) | -7.66 | -11.49 | -14.04 | -10.13 | -10.35 | |
| Free Cash Flow | -51.79 | -74.24 | -83.46 | -60.42 | -42.75 | |
| Free Cash Flow Per Share | -7.08 | -10.18 | -11.50 | -8.97 | -8.10 | |
| Operating Margin | - | - | -1503.39% | - | - | |
| Profit Margin | - | - | -1455.29% | - | - | |
| Free Cash Flow Margin | - | - | -1192.21% | - | - | |
| EBITDA | -51.37 | -88.1 | -104.17 | -70.14 | -53.15 | |
| D&A For EBITDA | 0.9 | 1.04 | 1.07 | 1.02 | 1.51 | |
| EBIT | -52.27 | -89.14 | -105.24 | -71.16 | -54.66 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.